keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunoglobulin

keyword
https://www.readbyqxmd.com/read/29765591/a-case-of-periorbital-necrotizing-fasciitis-rapidly-progressing-to-severe-multiorgan-failure
#1
Paola Eiben, Sancho Rodriguez-Villar
Periorbital necrotizing fasciitis (PNF) is a severe suppurative infection of the subcutaneous tissue and underlying fascia of the periorbital region. Typically, the course of PNF is milder and has a better prognosis than that of necrotizing fasciitis in other parts of the body. As such, this disease is thought to be associated with a significantly smaller risk of morbidity and mortality. Nevertheless, it is a rare and devastating condition that can lead to disfigurement, blindness and death. Early recognition is critical to improved patient outcomes...
April 2018: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/29761739/efficacy-safety-and-quality-of-life-in-patients-receiving-subcutaneous-igg-treatment-experience-in-bogot%C3%A3-colombia
#2
María Claudia Ortega-López, Javier Garay, Mónica León Pinilla
AIM: Investigate efficacy, safety and quality of life of gammanorm® 16.5% (subcutaneous immunoglobulin [SCIG]) in patients with primary immunodeficiencies (PIDs) and safety and to lesser extent efficacy in autoimmune diseases. PATIENTS & METHODS: Medical records were extracted from 31 pediatric and 12 adult patients who received SCIG as part of the Personalized Program at University Children's Hospital, Bogotá, Colombia. RESULTS: Mean SCIG dose was 28...
May 15, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29761122/bortezomib-treatment-for-severe-refractory-anti-nmda-receptor-encephalitis
#3
Yong-Won Shin, Soon-Tae Lee, Tae-Joon Kim, Jin-Sun Jun, Kon Chu
Objective: To evaluate the therapeutic potential of bortezomib, a proteasome inhibitor that target plasma cells, in order to revive stalled recovery in patients with anti- N -methyl-d-aspartate (NMDA) receptor encephalitis who remain bedridden even after aggressive immunotherapy. Methods: We consecutively enrolled patients with anti-NMDA receptor encephalitis who remained bedridden after first-line immunotherapy (steroids and intravenous immunoglobulin), second-line immunotherapy (rituximab), and tocilizumab treatment, and treated them with subcutaneous bortezomib...
May 2018: Annals of Clinical and Translational Neurology
https://www.readbyqxmd.com/read/29752963/ses-proteins-as-possible-targets-for-vaccine-development-against-staphylococcus-epidermidis-infections
#4
Dorien Hofmans, Laleh Khodaparast, Ladan Khodaparast, Els Vanstreels, Mohammad Shahrooei, Johan Van Eldere, Lieve Van Mellaert
OBJECTIVES: The opportunistic pathogen Staphylococcus epidermidis is progressively involved in device-related infections. Since these infections involve biofilm formation, antibiotics are not effective. Conversely, a vaccine can be advantageous to prevent these infections. In view of vaccine development, predicted surface proteins were evaluated on their potential as a vaccine target. METHODS: Immunoglobulins directed against S. epidermidis surface proteins SesB, M, O, Q and R, were used to firstly affirm their surface location...
May 9, 2018: Journal of Infection
https://www.readbyqxmd.com/read/29752757/subcutaneous-immunotherapy-suppresses-th2-inflammation-and-induces-neutralizing-antibodies-but-sublingual-immunotherapy-suppresses-airway-hyperresponsiveness-in-grass-pollen-mouse-models-for-allergic-asthma
#5
Laura Hesse, Uilke Brouwer, Arjen H Petersen, Renée Gras, Lisette Bosman, Jens Brimnes, Joanne N G Oude Elberink, Antoon J M van Oosterhout, Martijn C Nawijn
BACKGROUND: Both subcutaneous and sublingual allergen immunotherapy (SCIT and SLIT) have been shown to effectively suppress allergic manifestations upon allergen exposure, providing long term relief from symptoms in allergic disorders including allergic asthma. Clinical studies directly comparing SCIT and SLIT report a different kinetics and magnitude of immunological changes induced during treatment. Comparative studies into the mechanisms underlying immune suppression in SCIT and SLIT are lacking...
May 12, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29744206/effects-of-the-methacrylate-acrylate-monomers-hema-tegdma-degda-and-ema-on-the-immune-system
#6
Sara Alizadehgharib, Anna-Karin Östberg, Ulf Dahlgren
Incomplete curing of dental fillings may lead to leakage of methacrylate/acrylate monomers, which may come in contact with different cells of the immune system in oral tissues. Very little is known about the different immunologic effects caused by these methacrylates/acrylates. The objective of the present study was to study if and how the methacrylate/acrylate monomers ethyl methacrylate (EMA) and diethylene glycol diacrylate (DEGDA) affect the immune system in vivo and in vitro in comparison to 2-hydroxyethyl methacrylate (HEMA) and triethylene glycol dimethacrylate (TEGDMA)...
December 2017: Clinical and Experimental Dental Research
https://www.readbyqxmd.com/read/29713933/correction-to-assessment-of-local-adverse-reactions-to-subcutaneous-immunoglobulin-scig-in-clinical-trials
#7
Mark Ballow, Richard L Wasserman, Stephen Jolles, Helen Chapel, Mel Berger, Siraj A Misbah
The article Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials, written by Mark Ballow, Richard L. Wasserman, Stephen Jolles, Helen Chapel, Mel Berger, Siraj A. Misbah, was originally published Online First without open access.
April 27, 2018: Journal of Clinical Immunology
https://www.readbyqxmd.com/read/29707828/enhanced-immunity-in-intradermal-vaccination-by-novel-hollow-microneedles
#8
N Ogai, I Nonaka, Y Toda, T Ono, S Minegishi, A Inou, M Hachiya, H Fukamizu
BACKGROUND: The intradermal (ID) route for vaccination represents an effective alternative to subcutaneous (SC)/intramuscular administration to induce protective immunity. However, a critical issue associated with ID vaccination is the precise delivery of solution in the upper dermis, which ensures enhanced immunity. METHODS: We fabricated a hollow microneedle unit made of poly-glycolic acid by injection molding and bonding, and created a dedicated prototype injector...
April 29, 2018: Skin Research and Technology
https://www.readbyqxmd.com/read/29701813/a-microneedle-patch-for-measles-and-rubella-vaccination-is-immunogenic-and-protective-in-infant-rhesus-macaques
#9
Jessica C Joyce, Timothy D Carroll, Marcus L Collins, Min-Hsin Chen, Linda Fritts, Joseph C Dutra, Tracy L Rourke, James L Goodson, Michael B McChesney, Mark R Prausnitz, Paul A Rota
Background: New methods to increase measles and rubella (MR) vaccination coverage are needed to achieve global and regional MR elimination goals. Methods: Here, we developed microneedle (MN) patches designed to administer MR vaccine by minimally trained personnel, leave no biohazardous sharps waste, remove the need for vaccine reconstitution, and provide thermostability outside the cold chain. This study evaluated the immunogenicity of MN patches delivering MR vaccine to infant rhesus macaques...
April 26, 2018: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29692618/an-evaluation-of-the-budget-impact-of-a-new-20-subcutaneous-immunoglobulin-ig20gly-for-the-management-of-primary-immunodeficiency-diseases-in-switzerland
#10
Richard F Pollock, Lisa M Meckley
Introduction: While most individual primary immunodeficiency diseases (PID) are rare, the collective prevalence of PID results in a substantial economic and clinical burden. The aim of this study was to evaluate the budgetary implications of Ig20Gly (Immune Globulin Subcutaneous [human] 20% solution; CUVITRU ® , Baxalta US Inc, now part of Shire Plc, Westlake Village, CA, USA) as a treatment for PID relative to intravenous immunoglobulin (IVIG) and other subcutaneous immunoglobulin (SCIG) formulations in the Swiss health care setting...
2018: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/29686117/comprehensive-systematic-review-summary-disease-modifying-therapies-for-adults-with-multiple-sclerosis-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#11
Alexander Rae-Grant, Gregory S Day, Ruth Ann Marrie, Alejandro Rabinstein, Bruce A C Cree, Gary S Gronseth, Michael Haboubi, June Halper, Jonathan P Hosey, David E Jones, Robert Lisak, Daniel Pelletier, Sonja Potrebic, Cynthia Sitcov, Rick Sommers, Julie Stachowiak, Thomas S D Getchius, Shannon A Merillat, Tamara Pringsheim
OBJECTIVE: To review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and progressive MS forms. METHODS: Relevant, peer-reviewed research articles, systematic reviews, and abstracts were identified (MEDLINE, CENTRAL, EMBASE searched from inception to November 2016). Studies were rated using the therapeutic classification scheme. Prior published Cochrane reviews were also used...
April 24, 2018: Neurology
https://www.readbyqxmd.com/read/29679487/allergen-specific-immunotherapy-induces-regulatory-t-cells-in-an-atopic-dermatitis-mouse-model
#12
Jung U Shin, Seo Hyeong Kim, Ji Yeon Noh, Ji Hye Kim, Kim Hye Ran, Kyoung Yong Jeong, Kyung Hee Park, Jungsoo Lee, Howard Chu, Jae-Hyun Lee, Tai-Soon Yong, Jung-Won Park, Kwang Hoon Lee
BACKGROUND: Several studies have demonstrated that allergen-specific immunotherapy (SIT) can be an effective treatment for atopic dermatitis (AD). However, there is no relevant mouse model to investigate the mechanism and validate the novel modality of SIT in AD. METHODS: NC/Nga mice with induced AD-like skin lesions received a subcutaneous injection of SIT (an extract of the house dust mite Dermatophagoides farinae [DfE]) or placebo for 5 weeks). Clinical and histological improvements of AD-like skin lesions were examined...
April 21, 2018: Allergy
https://www.readbyqxmd.com/read/29671280/efficacy-and-safety-of-subcutaneous-belimumab-in-anti-dsdna-positive-hypocomplementemic-patients-with-systemic-lupus-erythematosus
#13
A Doria, W Stohl, A Schwarting, M Okada, M Scheinberg, R van Vollenhoven, A E Hammer, J Groark, D Bass, N L Fox, D Roth, D Gordon
OBJECTIVE: To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 [<90 mg/dL] and/or C4 [<10 mg/dL]) and anti-double-stranded(ds)DNA-positive (≥30 IU/mL) at baseline. METHODS: This Phase III, double-blind, placebo-controlled study (BEL112341; NCT01484496) randomized patients (2:1) with moderate-to-severe SLE (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index ≥8) to weekly subcutaneous (SC) belimumab 200 mg or placebo, plus standard SLE therapy, for 52 weeks...
April 18, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29670279/safety-pharmacokinetics-and-biomarkers-of-f-652-a-recombinant-human-interleukin-22-dimer-in-healthy-subjects
#14
Kai-Yang Tang, Jason Lickliter, Zhi-Hua Huang, Zong-Shu Xian, Han-Yang Chen, Cheng Huang, Chong Xiao, Yu-Peng Wang, Ying Tan, Lin-Feng Xu, Yu-Liang Huang, Xiao-Qiang Yan
F-652 is a recombinant fusion protein consisting of two human interleukin-22 (IL-22) molecules linked to an immunoglobulin constant region (IgG2 -Fc). IL-22 plays critical roles in promoting tissue repair and suppressing bacterial infection. The safety, pharmacokinetics (PK), tolerability, and biomarkers of F-652 were evaluated following a single dose in healthy male volunteers in a randomized, double-blind, placebo-controlled study. Following single-dose subcutaneous (SC) injection of F-652 at 2.0 µg/kg into healthy subjects, six out of six subjects experienced delayed injection site reactions, which presented as erythematous and/or discoid eczematous lesions 10 to 17 days post-dosing...
April 18, 2018: Cellular & Molecular Immunology
https://www.readbyqxmd.com/read/29657706/kimura-s-disease-of-the-parotid-gland-with-cutaneous-features-in-a-caucasian-female-patient
#15
Natalia Glibbery, Kenneth Muscat, Luke Cascarini
Kimura's disease is a rare disease of unknown aetiology, commonly presenting with slow-growing head and neck subcutaneous nodules, lymphadenopathy, eosinophilia and elevated immunoglobulin E. This report describes a very rare case of a 41-year-old female, of White-British ethnicity, with a new diagnosis of Kimura's disease of the parotid gland and associated cutaneous features. The patient was investigated for 3 years before a diagnosis of Kimura's disease was reached. A superficial parotidectomy was undertaken and no recurrence was observed in the 20 months following surgery...
April 2018: Journal of Surgical Case Reports
https://www.readbyqxmd.com/read/29644723/a-french-observational-study-describing-the-use-of-human-polyvalent-immunoglobulins-in-hematological-malignancy-associated-secondary-immunodeficiency
#16
Omar Benbrahim, Jean-François Viallard, Sylvain Choquet, Bruno Royer, Frédéric Bauduer, Olivier Decaux, Jean-Charles Crave, Yann Fardini, Pierre Clerson, Vincent Levy
OBJECTIVE: To describe the characteristics of patients suffering from secondary immunodeficiencies (SID) associated with hematological malignancies (HM), who started immunoglobulins replacement therapy (IgRT), physicians' expectations regarding IgRT and IgRT modalities. METHODS: Non-interventional, prospective French cross-sectional study. RESULTS: The analysis included 231 patients (66±12 years old) suffering from multiple myeloma (MM) (N=64), chronic lymphoid leukemia (CLL) (N=84), aggressive non-Hodgkin B-cell lymphoma (aNHL) (N=32), indolent NHL (N=39), acute leukemia (N=6), Hodgkin disease (N=6)...
April 12, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/29625665/subcutaneous-venom-immunotherapy-in-children-efficacy-and-safety
#17
Pınar Gür Çetinkaya, Saliha Esenboğa, Özge Uysal Soyer, Ayfer Tuncer, Bülent Enis Şekerel, Ümit Murat Şahiner
BACKGROUND: Venom immunotherapy (VIT) is safe in children, although adverse effects can occur. OBJECTIVE: To document adverse effects and to determine re-sting reactions and the efficacy of VIT in childhood. METHODS: We retrospectively analyzed data from children who had taken VIT from 2002 through 2015. These patients were queried by telephone to determine reactions after re-stings during or after VIT. RESULTS: In total 107 children with a systemic reaction after Hymenoptera sting and with proved immunoglobulin E-mediated sensitization were enrolled...
April 2018: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/29618922/in-depth-interviews-of-patients-with-primary-immunodeficiency-who-have-experienced-pump-and-rapid-push-subcutaneous-infusions-of-immunoglobulins-reveal-new-insights-on-their-preference-and-expectations
#18
Grégoire Jacques Noël Cozon, Pierre Clerson, Annaïk Dokhan, Yann Fardini, Taylor Pindi Sala, Jean-Charles Crave
Purpose: Patients with primary immunodeficiency (PID) often receive immunoglobulin replacement therapy (IgRT). Physicians and patients have the choice between various methods of administration. For subcutaneous immunoglobulin infusions, patients may use an automated pump (P) or push the plunger of a syringe (rapid push [RP]). P infusions are performed once a week and last around 1 hour. RP decreases the duration of administration, but requires more frequent infusions. Patients and methods: Eight out of 30 patients (coming from a single center) who had participated in the cross-over, randomized, open-label trial comparing P and RP participated in a focus group or underwent in-depth interviews...
2018: Patient Preference and Adherence
https://www.readbyqxmd.com/read/29614902/intravenous-immunoglobulin-ivig-efficiency-in-women-with-common-variable-immunodeficiency-cvid-decreases-significantly-during-pregnancy
#19
Makiko Egawa, Hirokazu Kanegane, Kohsuke Imai, Tomohiro Morio, Naoyuki Miyasaka
Immunoglobulin replacement therapy, including intravenous immunoglobulin (IVIG), is essential for pregnant women with common variable immunodeficiency (CVID) since it prevents infection and improves the health of the newborn. There are no established IVIG treatment protocols for pregnant women with CVID, and the relationship between IVIG treatment and maternal serum IgG changes during pregnancy remains unclear. Therefore, we reviewed the medical charts of four CVID patients, including one receiving subcutaneous immunoglobulin (SCIG), for IVIG dose and frequency, maternal serum IgG changes, obstetrical findings, and perinatal outcomes...
April 3, 2018: Journal of Maternal-fetal & Neonatal Medicine
https://www.readbyqxmd.com/read/29578578/confirmatory-population-pharmacokinetic-analysis-for-sirukumab-a-human-monoclonal-antibody-targeting-interleukin-6-in-patients-with-moderately-to-severely-active-rheumatoid-arthritis
#20
Yan Xu, Chuanpu Hu, Yanli Zhuang, Benjamin Hsu, Zhenhua Xu, Honghui Zhou
The population pharmacokinetics of sirukumab, a human immunoglobulin G1κ monoclonal antibody against interleukin-6, were characterized in patients with moderately to severely active rheumatoid arthritis in 4 phase 3 studies (SIRROUND-D, -T, -H, and -M). A total of 17 034 serum concentrations were analyzed from 1991 rheumatoid arthritis patients who received subcutaneous administration of sirukumab 50 mg every 4 weeks or 100 mg every 2 weeks. A stepwise confirmatory population PK analysis was conducted to accommodate the staged data release and the sparse sampling nature of phase 3 studies and to assess the potential covariate influences in an unbiased and timely manner...
March 26, 2018: Journal of Clinical Pharmacology
keyword
keyword
54047
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"